RecruitingPriority 3 · Moderate priorityNCT05157581
Extracorporeal Photopheresis in Sezary Syndrome
Plain-language summary
This study is studying Extracorporeal photopheresis (ECP) and Methoxsalen Injection for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 3 US locations.
Who can join (key eligibility)
- Age 18 Years to 100 Years years
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Extracorporeal photopheresis (ECP) (DEVICE): Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body. | Methoxsalen Injection (DRUG): Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
- Drugs / treatments
- Extracorporeal photopheresis (ECP), Methoxsalen Injection
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details